Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant

摘要

Helicobacter pylori (H.pylori) infection remains a significant global public health problem. Vaccine, especially edible vaccine, is considered to be effective in the management of H.pylori infections. By using recombinant technology, Lactococcus lactis (L.lactis) could serve as an antigen-delivering vehicle for the development of edible vaccine. The aim of this study was to produce edible UreB (urease B) vaccine derived from L.lactis against H.pylori. The UreB subunit is the most effective and common immunogen of all strains of H.pylori. The UreB was produced as a chimeric protein fused with IL-2 (human interleukin 2) as the mucosal adjuvant. Mucosal immunization of mice with recombinant L.lactis NZ9000 containing the UreB-IL-2 protein elicited more anti-UreB antibody that specifically bounded to the purified bacterial UreB protein and more cytokines such as IFN-γ, IL-4, and IL-17, and had a lower H.pylori burden and urease activity than control mice. These results suggest that the recombinant L.lactis expressing UreB-IL-2 can be potentially used as an edible vaccine for controlling H.pylori infection.